rTMS Intervention for Hypermetria
Phase-Based Progress Estimates
Effectiveness
Safety
Moss Rehabilitation Research Institute, Elkins Park, PA
Hypermetria+1 More
Transcranial Magnetic Stimulation (TMS) - DeviceEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This study will determine (1) whether baseline inhibitory activity in the primary motor cortex can predict motor learning ability in individuals with cerebellar degeneration, and (2) whether modulating primary motor cortex activity with non-invasive brain stimulation alters motor learning ability in this population.
Eligible Conditions
- Hypermetria
Treatment Effectiveness
Effectiveness Progress
Study Objectives
7 Primary · 0 Secondary · Reporting Duration: Baseline
Baseline
Cortical Silent Period
International Cooperative Ataxia Rating Scale Limb Coordination Sub-Score
International Cooperative Ataxia Rating Scale Total Score
Slope of the Corticomotor Excitability Recruitment Curve
Slope of the Short-Interval Intracortical Inhibition (SICI) Recruitment Curve
Day 10
Reinforcement Learning Rate
Total Reinforcement Learning
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
rTMS Intervention
1 of 1
Experimental Treatment
12 Total Participants · 1 Treatment Group
Primary Treatment: rTMS Intervention · No Placebo Group · N/A
rTMS Intervention
Device
Experimental Group · 1 Intervention: Transcranial Magnetic Stimulation (TMS) · Intervention Types: DeviceTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation (TMS)
2018
Completed Phase 4
~400
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline
Trial Background
Amanda Therrien, PhD
Principal Investigator
Albert Einstein Healthcare Network
Closest Location: Moss Rehabilitation Research Institute · Elkins Park, PA
2010First Recorded Clinical Trial
0 TrialsResearching Hypermetria
3 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments